Diltiazem is a calcium antagonist used in angina pectoris and hypertension. There is little information concerning the slow-release (SR) formulation in the literature. The pharmacokinetics of diltiazem SR (120 mg) have been assessed over a 36 h period in healthy volunteers after single-(SD) and mult
Pharmacokinetics of slow-release diltiazem and its effect on atrioventricular conduction in healthy volunteers
✍ Scribed by A. Gordin; P. Pohto; S. Sundberg; S. Nykänen; H. Haataja; P. Männistö
- Publisher
- Springer
- Year
- 1986
- Tongue
- English
- Weight
- 471 KB
- Volume
- 31
- Category
- Article
- ISSN
- 0031-6970
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
The pharmacokinetics of diltiazem were studied in seven patients with chronic renal failure (CRF) not requiring dialysis and in three healthy volunteers after a rapid i.v. infusion of 20mg. Mean plasma concentrations at the end of infusion were 3.15 times higher in patients with CRF than in healthy
We previously showed that oseltamivir, a prodrug of the influenza virus neuraminidase inhibitor Ro 64-0802, is a substrate of proton-coupled oligopeptide transporter (PEPT1), and its intestinal absorption in rats is markedly inhibited by administration with milk. To investigate the importance of PEP
STEVE TOON' AND MARGHERITA STROLIN-BENEDETTI. ## ABSTRA<JT The effect of food on the pharmacokinetics and tolerability of cabergoline in man was investigated. For this purpose an open, randomized, single-dose study was conducted in 12 healthy male volunteers who received 1 mg cabergoline as table